Buprenorphine Synthesis Yield and Purity Optimization

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current processes for synthesizing buprenorphine result in low yields and high levels of impurities, failing to meet the purity standards set by ICH and USP guidelines.

Innovation Solution

A six-step process involving specific chemical reactions and solvents, including a Diels-Alder reaction, hydrogenation, and alkylation, to produce buprenorphine with reduced impurity formation and increased yield, utilizing compounds like thebaine and oripavine as starting materials.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If traditional multi-step synthesis processes are used to produce buprenorphine, then the production process can be established, but the yield is low and impurity levels are high

Engineering Contradiction:
Improveyield of buprenorphineVSAvoidpurity of buprenorphine
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The patent applies parameter changes by optimizing reaction conditions including using specific solvents (acetonitrile, dichloromethane, or ethyl acetate), controlling temperature ranges (0-25°C for alkylation step), and adjusting reagent ratios to maximize yield while minimizing impurities. The process parameters are carefully tuned to achieve both high productivity and manufacturing precision

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses intermediary compounds and reagents to facilitate the synthesis. Specifically, it employs alkyl halides as intermediates in the alkylation step, and uses phase transfer catalysts or specific solvent systems to mediate the reaction between thebaine/oripavine and the desired products, thereby improving both yield and purity

Inventive Principle:
Principle #24Intermediary (Mediator)

2Manufacturing precision

If traditional synthesis routes from thebaine or oripavine are used, then buprenorphine can be produced, but impurity levels exceed ICH and USP guidelines

Engineering Contradiction:
Improvepurity of buprenorphineVSAvoidyield of buprenorphine
Core Design Contradiction:
Manufacturing precisionVSProductivity

Solution Approach 1:

The patent applies extraction principles by selectively removing or preventing the formation of impurity compounds during the synthesis process. The optimized reaction conditions and selective reagents are designed to take out unwanted side products while retaining the desired buprenorphine, thereby achieving high purity that meets ICH and USP guidelines

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs dynamic control of reaction conditions, including staged addition of reagents, temperature programming, and real-time monitoring of reaction progress. This dynamic approach allows the process to adapt to changing reaction conditions, maximizing both purity and yield at different stages of the synthesis

Inventive Principle:
Principle #15Dynamics

3Productivity

If multiple synthesis steps are performed to convert thebaine or oripavine to buprenorphine, then the desired compound can be formed, but the overall yield remains low

Engineering Contradiction:
Improveoverall yield of buprenorphineVSAvoidnumber of synthesis steps
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent applies merging by combining multiple reaction steps into a more integrated process flow. The optimized synthesis route consolidates transformations, uses compatible solvent systems that can carry through multiple steps, and employs reagents that perform multiple functions, thereby reducing the effective number of discrete steps while maintaining high overall yield

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The patent applies preliminary action by pre-preparing and purifying key intermediates before the final transformation to buprenorphine. The starting materials (thebaine or oripavine) are pre-treated and activated in optimized conditions, and potential impurities are removed in advance, which prevents carryover of impurities through subsequent steps and maximizes overall yield

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process significantly increases the yield of buprenorphine to greater than 10% and reduces impurities to less than 0.15% by weight, ensuring the final product meets the required purity standards.

Implementation Method 1

A six-step process involving specific chemical reactions and solvents, including a Diels-Alder reaction

Methodology Applied
Scientific EffectDiels-Alder reaction: Chemical Bonding

Implementation Method 2

A six-step process involving specific chemical reactions and solvents, including a Diels-Alder reaction, hydrogenation, and alkylation

Methodology Applied
Scientific EffectHydrogenation: Hydrogenation

Implementation Method 3

A six-step process involving specific chemical reactions and solvents, including a Diels-Alder reaction, hydrogenation, and alkylation

Methodology Applied
Scientific EffectAlkylation: Chemical Bonding

Data Source

PatentEP2344509B1Processes for the production of buprenorphine with reduced impurity formation
Publication Date: 2015.11.11 MALLINCKRODT LLC
  • EP2344509B1 patent drawingFigure 1
  • EP2344509B1 patent drawingFigure 2
  • EP2344509B1 patent drawing

AI summary

The present invention provides process for the production of opiate alkaloids. In particular, the present invention provides processes for the production of buprenorphine or a derivative of buprenorphine that minimizes the formation of impurities.